Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still…
FIREFLY-1 clinical abstract selected for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Leadership team…
Nanox.ARC Image of the Nanox ARC Nanox.ARC Image of the Nanox ARCNanox.ARC presents high powered digital X-ray tubes for 3D…
Strategic role strengthens NeuroStar® Advanced Therapy commercialization teamMALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a…
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Caira Surgical, the pioneer in radar surgical tracking for navigated and robotic…
Broad Formulation Patent Expands Protection for GimotiSOLANA BEACH, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty…
Availability: OLPRUVA™ drug in channel now anticipated in mid-June 2023 Awareness: 70% of metabolic treatment providers surveyed by Acer at…
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a…
Submission of Investigational New Drug application expected in the second quarter of 2023 with start of Phase 1 trial expected…
BMF-500, a novel 3rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and…